Cover Image
市場調查報告書

全球動物用抗感染藥市場:各動物疾病、技術、動物、地區 - 趨勢及預測

Global Veterinary Anti-infectives market Segmented by Veterinary disease types, by animal types & By Geography - Trends & Forecasts 2016-2021

出版商 Mordor Intelligence LLP 商品編碼 319398
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球動物用抗感染藥市場:各動物疾病、技術、動物、地區 - 趨勢及預測 Global Veterinary Anti-infectives market Segmented by Veterinary disease types, by animal types & By Geography - Trends & Forecasts 2016-2021
出版日期: 2016年08月01日 內容資訊: 英文 190 Pages
簡介

全球動物用抗感染藥市場預計2014年達43億7,000萬美元。預期該市場今後也以年複合成長率8.5%擴大,至2019年達到69億2,000萬美元。為了對應動物感染疾病的病例增加,動物用抗感染藥市場踏實成長。

本報告提供全球動物用抗感染藥市場趨勢與未來預測,打入市場的主要企業的競爭環境,市場佔有率,近幾年趨勢與簡介彙整。

第1章 簡介

第2章 市場分析

  • 動物醫療產品市場
  • 動物醫療和人的醫療

第3章 市場趨勢

  • 推動市場的要素
    • 寵物擁有率的上升
    • 營養的改善
    • 消費者對食品安全的認知提高
    • 家畜生產的增加
    • 人畜共通感染疾病、經由食物傳染疾病
  • 阻礙市場的要素
    • 耕種地和水的不足
    • 耕地相關競爭激烈
    • 成本效益高的生產
  • 波特五力分析

第4章 全球動物用抗感染藥市場區隔

  • 全球動物用抗感染藥市場:各疾病
  • 全球動物用抗感染藥市場:各類型
    • 寵物
    • 家畜
  • 全球動物用抗感染藥市場:各地區
    • 北美
    • 歐洲
    • 亞太地區

第5章 競爭環境

  • 市場上主要加入企業
  • 合併、收購
  • 新產品上市
  • 協定、聯合、聯盟

第6章 企業簡介

  • Zoetis animal healthcare
  • Merck
  • Merial (Animal Health Division Of Sanofi)
  • Elanco
  • Bayer healthcare
  • Novartis Animal Health, Inc.
  • Virbac
  • Boehringer Ingelheim

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global market for veterinary anti-infectives is estimated to be worth USD 4,298 million in 2014. Expected to grow at a healthy CAGR of 6.35%, the market is set to reach USD 6,218 million by 2020. Global veterinary healthcare offers services and products in various segments such as vaccines, parasiticides, anti-infectives, medicinal feed additives, other pharmaceuticals, out of which anti-infectives are growing at a steady pace to combat the increasing number of infectious diseases in animals. It is the second best segment after vaccines and holds about 20% of the global animal healthcare market share.

Global Veterinary Anti-Infectives Market- Market Dynamics

The report studies various driving and restraining factors for the global veterinary anti-infectives market. Some of these are listed below.

Drivers

  • Increase in pet ownership
  • Improved nutrition
  • Increasing zoonotic and foodborne diseases

Restraints

Increased competition for cultivated land and cost-effective production are the major obstacles in the path of global veterinary anti-infectives market.

The report highlights the segment-wise contribution of different anti-incentives by disease, species, and geography. By type of products, the market has been segmented into marbofloxacin, florfenicol, freeze-dried ceftiofur, beta-lactams, oxytetracycline, and aminosidine; by species into companion and farm animals and by geography into North America, Asia-Pacific, Europe and Rest of World.

Some of the key players in the market are:

  • Bayer Healthcare
  • Boehringer Ingelheim
  • Ceva Animal Health, Inc.
  • Elanco
  • Merck
  • Merial (Animal Health Division of Sanofi)

What the Report Offers

  • Market definition for the specified topic along with identification of key drivers and restraints for the market.
  • Market analysis for the veterinary anti-infectives market, with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
  • Identification and analysis of the macro and micro factors that affect the veterinary anti-infectives market on both global and regional scale.
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Table of Contents

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Recent Trends

2.Market Analysis

  • 2.1. Market Animal Health Products
  • 2.2. Animal medicines vs. human Medicines

3.Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increase in pet ownership
    • 3.1.2. Improved Nutrition
    • 3.1.3. Intensifying consumer focus on food safety
    • 3.1.4. Greater Livestock production
    • 3.1.5. Increasing Zoonotic and Foodborne Diseases
  • 3.2. Market Constraints
    • 3.2.1. Scarcity of arable land and water
    • 3.2.2. Increased competition for cultivated land
    • 3.2.3. Cost effective production
  • 3.3. Porter's Five Force Analysis
    • 3.3.1. Threat of New Entrant
    • 3.3.2. Internal Rivalry
    • 3.3.3. Buyer bargaining power
    • 3.3.4. Supplier bargaining power
    • 3.3.5. Threat of substitutes

4.Global Veterinary Anti-Infective Market Segmentation

  • 4.1. Global Veterinary Anti-infectives Market, By disease
    • 4.1.1. Marbofloxacin
    • 4.1.2. Florfenicol
    • 4.1.3. Freeze-dried ceftiofur
    • 4.1.4. Beta-lactams
    • 4.1.5. Oxytetracycline
    • 4.1.6. Aminosidine
  • 4.2. Global Veterinary Anti-Infectives Market, By species
    • 4.2.1. Companion Animals
      • 4.2.1.1Dogs
      • 4.2.1.2. Cats
      • 4.2.1.2. Horses
    • 4.2.2. Farm animal
      • 4.2.2.1. Cattle
      • 4.2.2.2. Swine
      • 4.2.2.3. Poultry
      • 4.2.2.4. Fish
      • 4.2.2.5. Sheep
  • 4.3. Global Veterinary Anti-Infectives Market Segmentation, By Geography
    • 4.3.1. North America
      • 4.3.1.1. US
      • 4.3.1.2. Mexico
      • 4.3.1.3. Canada
    • 4.3.2. Europe
      • 4.3.2.1. France
      • 4.3.2.2. Italy
      • 4.3.2.3. Germany
      • 4.3.2.4. Spain
      • 4.3.2.5. Sweden
      • 4.3.2.6. Rest of Europe
    • 4.3.3. Asia-Pacific
      • 4.3.3.1. India
      • 4.3.3.2. China
      • 4.3.3.3. Japan
      • 4.3.3.4. Rest of Asia-Pacific
    • 4.3.4. Rest of the World

5. Competitive landscape

  • 5.1. Major players in the market
  • 5.2. mergers and acquisitions
  • 5.3. New product launches
  • 5.4. Agreement, Collaborations, and Partnerships
  • 5.5. Recommendations for New players in the market
  • 5.6. Recommendations for Existing players in the market

6. Company profiles

  • 6.1. Zoetis animal healthcare
    • 6.1.1. Financial Overview
    • 6.1.2. Business overview
    • 6.1.3. Business strategies
  • 6.2. Merck
    • 6.2.1. Financial Overview
    • 6.2.2. Business overview
    • 6.2.3. Business strategies
  • 6.3. Merial (Animal Health Division Of Sanofi)
    • 6.3.1. Financial Overview
    • 6.3.2. Business overview
    • 6.3.3. Business strategies
  • 6.4. Elanco
    • 6.4.1. Financial Overview
    • 6.4.2. Business overview
    • 6.4.3. Business strategies
  • 6.5. Bayer healthcare
    • 6.5.1. Financial Overview
    • 6.5.2. Business overview
    • 6.5.3. Business strategies
  • 6.6. Ceva Animal Health, Inc.
    • 6.6.1. Financial Overview
    • 6.6.2. Business overview
    • 6.6.3. Business strategies
  • 6.7. Virbac
    • 6.7.1. Financial Overview
    • 6.7.2. Business overview
    • 6.7.3. Business strategies
  • 6.8. Boehringer Ingelheim
    • 6.8.1. Financial Overview
    • 6.8.2. Business overview
    • 6.8.3. Business strategies

7. Appendix

  • 7.1. Abbreviations
  • 7.2. Sources
  • 7.3. Bibliography
  • 7.4. Disclaimer
Back to Top